Background illustration for clinical trials search

Pancreatic Cancer Clinical Trials

Browse 1,722 pancreatic cancer clinical trials enrolling across the United States and Canada. Search by city or state to find one near you.

Filter
1

Imaging Study of [89Zr]DFO-YS5 for Cancer Detection

for
Bladder Cancer, Nerve Sheath Tumor, Nerve Sheath Tumors,
Location: San Francisco CA
Sponsor: Robert Flavell, MD, PhD

Sex: All

Age: 18+

Code: NCT07664397

Phase 1, Recruiting

Ex Vivo Expansion (ACT-X)

for
Solid Tumor, Healthy, Malignant Solid Neoplasm
Location: Jacksonville FL
Sponsor: Mayo Clinic

Sex: All

Age: 18+

Code: NCT07137312

Recruiting

Adding Spatially Fractionated Radiation Therapy to Standard Palliative Radiation for Improving Disease-Related Symptoms in Patients With Unresectable Solid Tumors

for
Metastatic Malignant Solid Neoplasm,
Location: Rochester MN, Scottsdale AZ
Sponsor: Mayo Clinic

Sex: All

Age: 15+

Code: NCT07856394

Recruiting

Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer

for
Advanced Malignant Solid Neoplasm,
Location: Houston TX
Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT05111561

Phase 1, Recruiting

FORTRAS: A Study of MSK-TCR5 in People With Solid Tumor Cancers

for
Solid Tumor, Solid Carcinoma, Advanced Solid Tumor,
Location: Commack NY, Uniondale NY, Harrison NY, New York NY,
Sponsor: Memorial Sloan Kettering Cancer Center

Sex: All

Age: 18+

Code: NCT07638371

Phase 1, Recruiting

Interested in new trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image

Dose-Escalation and Dose-Expansion Study of BSI-082 Monotherapy and Combined Therapy in Patients With Advanced or Metastatic Solid Tumors

for
Solid Tumor, Advanced Solid Tumor, Metastatic Solid Tumor
Location: San Antonio TX
Sponsor: Lei Zheng

Sex: All

Age: 18+

Code: NCT07086768

Phase 1, Recruiting

NCI Childhood Cancer Data Initiative (CCDI) Led Pediatric, Adolescent, and Young Adult Rare Cancer Registry for Very Rare Solid Tumors

for
Very Rare Tumors, Very Rare Cancers, Other Solid Tumors,
Location: Bethesda MD
Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 0 - 70+

Code: NCT07489378

Recruiting

A First in Human Study of PLT012 in Participants With Solid Tumor Cancers

for
Advanced Malignant Solid Tumor, Solid Tumor Cancer
Location: Houston TX, Dallas TX, Los Angeles CA
Sponsor: Pilatus Biosciences Inc

Sex: All

Age: 18+

Code: NCT07337525

Phase 1, Recruiting

Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors

for
Cancer, Solid Tumor Cancer, Advanced Metastatic Cancer,
Location: Fairfax VA, Plantation FL, Austin TX, San Antonio TX
Sponsor: Conjupro Biotherapeutics, Inc.

Sex: All

Age: 18+

Code: NCT07424547

Phase 1, Recruiting

Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss

for
Advanced Cancer, Solid Tumor
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center

Sex: All

Age: 18+

Code: NCT07382544

Phase 1, Recruiting

WellSpan-THRIVE Cancer QOL Study

for
Cancer (Active Cancer, Meaning Not Being Cancer Free), of Any Stage and Involving Any Treatment/Care Regimen; i.e. Curative, Life-extending, or Palliative,
Location: Ephrata PA, Lebanon PA, York PA, Gettysburg PA,
Sponsor: WellSpan Health

Sex: All

Age: 18+

Code: NCT07433660

Recruiting

DESCANSO, a Mental Health Intervention for Depression, Insomnia, and Fatigue Symptoms in Latino People With Cancer

for
Solid Tumor, Solid Tumor, Adult
Location: Commack NY, Rockville Centre NY, Harrison NY,
Sponsor: Ponce Medical School Foundation, Inc.

Sex: All

Age: 21 - 70+

Code: NCT07225088

Recruiting

A Phase 1 Study of JMT108 in Participants With Advanced Solid Tumors

for
Cancer, Cancer (Solid Tumors)
Location: Fairfax VA, Huntersville NC, Dallas TX
Sponsor: Conjupro Biotherapeutics, Inc.

Sex: All

Age: 18+

Code: NCT07317505

Phase 1, Recruiting

A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer

for
Cutaneous Squamous Cell Carcinoma,
Location: Uniondale NY, New York NY, Middletown NJ, Montvale NJ,
Sponsor: Memorial Sloan Kettering Cancer Center

Sex: All

Age: 18+

Code: NCT05859074

Phase 1, Recruiting

xDRIVE for Florida-based Cancer Patients

for
Cancer, Neoplams, Refractory, Recurrence, Leukaemia, Lymphoma,
Location: Miami FL
Sponsor: First Ascent Biomedical Inc.

Sex: All

Age: 0+

Code: NCT07167381

Recruiting

MTI-301 for the Treatment of Metastatic or Unresectable and Refractory Solid Cancers

for
Metastatic Malignant Solid Neoplasm,
Location: Jacksonville FL
Sponsor: Mayo Clinic

Sex: All

Age: 18+

Code: NCT06911008

Phase 1, Recruiting

Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma

for
Recurrent Solid Tumor, Recurrent Ewing Sarcoma,
Location: Montreal, Washington D.C. DC, Toronto, Atlanta GA,
Sponsor: St. Jude Children's Research Hospital

Sex: All

Age: 1 - 30

Code: NCT04901702

Phase 1, Phase 2, Recruiting

CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma

for
Diffuse Midline Glioma, H3 K27-Altered,
Location: Boston MA, Valhalla NY, New York NY, Philadelphia PA,
Sponsor: Children's Oncology Group

Sex: All

Age: 1 - 21

Code: NCT04870944

Phase 1, Phase 2, Recruiting

BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001)

for
Solid Tumor Cancer, Locally Advanced, Metastatic Solid Tumors,
Location: Boston MA, New York NY, Houston TX, Austin TX,
Sponsor: Avenzo Therapeutics, Inc.

Sex: All

Age: 18+

Code: NCT07193511

Phase 1, Phase 2, Recruiting

5-Azacitidine Plus PD-1/PD-L1 Inhibitor With PD-1/PD-L1 Refractory Tumors

for
Solid Tumor, Locally Advanced Solid Tumor, Metastatic Tumor
Location: Iowa City IA
Sponsor: Mohammed Milhem

Sex: All

Age: 18 - 70+

Code: NCT07404332

Phase 1, Recruiting

What is pancreatic cancer?

The pancreas sits deep behind the stomach and makes both digestive enzymes and hormones like insulin. About 92 percent of pancreatic cancers start in the enzyme making cells, and this page is mostly about those. The other 8 percent are neuroendocrine tumors, which grow more slowly, have their own trials, and a five year survival of 72 percent against 8 percent. The pancreas gives no early warning. Jaundice, back pain, weight loss and new diabetes usually appear only after the cancer has grown or spread, and fewer than 20 percent of people can have surgery at diagnosis.

Smoking roughly doubles the risk, and type 2 diabetes, extra weight, chronic pancreatitis and family history raise it. About 10 percent of cases come from inherited mutations, so guidelines now recommend genetic testing for everyone diagnosed. That can change treatment and flag relatives who should be watched. The hope comes from biology. More than 90 percent of pancreatic cancers carry a KRAS mutation. That target was called undruggable for decades. Now several RAS inhibitors are in trials, with the first Phase 3 studies recruiting. Pancreatic cancer shares risk factors with type 2 diabetes and inherited genes with breast and ovarian cancer.

Article preview image

Our guide to new treatments for pancreatic cancer covers what has been approved and what is being tested.

Research Paving The Way To A New Treatment For Pancreatic Cancer

Types of pancreatic cancer clinical trials

Who can participate in pancreatic cancer clinical trials?

What causes pancreatic cancer?

The stages of pancreatic cancer, and why they matter for trials

How to enroll in a pancreatic cancer clinical trial